cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.18713100
title: City of Ostrava Strategic Plan Interviews

description: A series of interviews was conducted in 2021 as part of the preparations for the City of Ostrava's new Strategic Plan. Due to the sensitive nature of these interviews, access cannot be provided to the files themselves.
DOI: 10.15468/dl.4fvwk3
title: Occurrence Download

description: A dataset containing 2 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Campsurus povilla",
 "DecimalLatitude is not null",
 "DecimalLongitude is not null"
 ]
}

 The dataset includes 2 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032007-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.uxg62n
title: Occurrence Download

description: A dataset containing 487 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((6.0672 47.27012,15.04193 47.27012,15.04193 55.09961,6.0672 55.09961,6.0672 47.27012))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Aedes albopictus",
 "Year 2018-2026"
 ]
}

 The dataset includes 487 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032009-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25824/redu/a2sl4s
title: Dados da tese: A estratégia de desinformação do governo Bolsonaro durante a pandemia de Covid-19: uma análise das narrativas da ivermectina no Twitter/X

description: Os arquivos presentes nesse dataset foram utilizados para tese de doutorado em Política Cientítica e Tecnológica pelo Instituto de Geociências da UNICAMP. The files in this dataset were used for a doctoral thesis in Science and Technology Policy at the Institute of Geosciences, UNICAMP.
DOI: 10.5281/zenodo.18266459
title: Sensomic profiling of coffee leaf infusions: chemical–sensory markers for quality assessment

description: Contains all the raw data and the input datasets needed to reproduced the data analysis and results of the manuscript "Sensomic profiling of coffee leaf infusions: chemical–sensory markers for quality assessment". Python scripts, Jupiter Notebooks and mock files are available at https://github.com/daviderovelli/CoffeeLeafInfuses
DOI: 10.5281/zenodo.18266458
title: Sensomic profiling of coffee leaf infusions: chemical–sensory markers for quality assessment

description: Contains all the raw data and the input datasets needed to reproduced the data analysis and results of the manuscript "Sensomic profiling of coffee leaf infusions: chemical–sensory markers for quality assessment". Python scripts, Jupiter Notebooks and mock files are available at https://github.com/daviderovelli/CoffeeLeafInfuses
DOI: 10.15468/dl.s2h3jy
title: Occurrence Download

description: A dataset containing 27865 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Coccyzus melacoryphus",
 "Year is greater than or equal to 2000",
 "Year is less than or equal to 2026",
 "HasCoordinate is true"
 ]
}

 The dataset includes 27865 records from 68 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032010-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.2sjxev
title: Occurrence Download

description: A dataset containing 22 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is CHN.29_1",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Pantholops hodgsonii"
 ]
}

 The dataset includes 22 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032011-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.18713205
title: JEPEX-ANGSTROM v127.0: Crystallization of a Quantum Attractor in Noisy Hardware (6 Qubits, ibm\_torino
DOI: 10.5281/zenodo.18713204
title: JEPEX-ANGSTROM v127.0: Crystallization of a Quantum Attractor in Noisy Hardware (6 Qubits, ibm\_torino
DOI: 10.6084/m9.figshare.28287310
title: Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

description: We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10<sup>10</sup> viral particles [vp]) in healthy adolescents aged 12–17 years. Participants were randomly assigned to receive Ad26.COV2.S at reduced dose levels of 0.625 × 10<sup>10</sup> (0.5 mL), 1.25 × 10<sup>10</sup> (0.5 mL) or 2.5 × 10<sup>10</sup> (0.5 mL or low volume 0.25 mL) vp in a 1- or 2-dose (56-day interval) primary schedule. Adolescents who received a 1-dose primary schedule received a 2.5 × 10<sup>10</sup> vp booster dose 6 months later. Safety and humoral immunogenicity were assessed up to 6 months post-last vaccination. All regimens were well tolerated, with no safety concerns identified. Local and systemic solicited AEs in adolescents were consistent with the known safety profile in adults. All 1- and 2-dose Ad26.COV2.S primary schedules elicited robust peak Spike-binding antibody responses and virus neutralizing titers against the reference strain, in participants with and without preexisting SARS-CoV-2 immunity. Immune responses were durable for at least 6 months. Spike-binding antibody responses were comparable to those elicited in young adults aged 18–25 years who received a standard dose of Ad26.COV2.S in Phase 3 efficacy studies Reduced doses/dose volume of Ad26.COV2.S had an acceptable safety profile and elicited robust humoral immune responses in adolescents aged 12–17 years. All 1- and 2-dose schedules elicited Spike-binding antibody responses that were comparable to an adult population in whom efficacy has been demonstrated using a higher vaccine dose. (clinicaltrials.gov NCT05007080).
DOI: 10.6084/m9.figshare.28287310.v1
title: Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

description: We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10<sup>10</sup> viral particles [vp]) in healthy adolescents aged 12–17 years. Participants were randomly assigned to receive Ad26.COV2.S at reduced dose levels of 0.625 × 10<sup>10</sup> (0.5 mL), 1.25 × 10<sup>10</sup> (0.5 mL) or 2.5 × 10<sup>10</sup> (0.5 mL or low volume 0.25 mL) vp in a 1- or 2-dose (56-day interval) primary schedule. Adolescents who received a 1-dose primary schedule received a 2.5 × 10<sup>10</sup> vp booster dose 6 months later. Safety and humoral immunogenicity were assessed up to 6 months post-last vaccination. All regimens were well tolerated, with no safety concerns identified. Local and systemic solicited AEs in adolescents were consistent with the known safety profile in adults. All 1- and 2-dose Ad26.COV2.S primary schedules elicited robust peak Spike-binding antibody responses and virus neutralizing titers against the reference strain, in participants with and without preexisting SARS-CoV-2 immunity. Immune responses were durable for at least 6 months. Spike-binding antibody responses were comparable to those elicited in young adults aged 18–25 years who received a standard dose of Ad26.COV2.S in Phase 3 efficacy studies Reduced doses/dose volume of Ad26.COV2.S had an acceptable safety profile and elicited robust humoral immune responses in adolescents aged 12–17 years. All 1- and 2-dose schedules elicited Spike-binding antibody responses that were comparable to an adult population in whom efficacy has been demonstrated using a higher vaccine dose. (clinicaltrials.gov NCT05007080).
DOI: 10.6084/m9.figshare.29148999
title: rLVS Δ<i>capB</i>/Yp F1-V single vector platform vaccine expressing <i>Yersinia pestis</i> F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli

description: <i>Yersinia pestis</i>, the causative agent of plague, is classified as a Tier I Select Agent of bioterrorism and is among a few pathogens of high concern as a potential cause of a future pandemic. Currently, there is no licensed vaccine against plague. Previously, we developed a live attenuated vaccine candidate, rLVS Δ<i>capB</i>/Yp F1-V, that utilizes a highly attenuated <i>capB</i> mutant of <i>Francisella tularensis</i> Live Vaccine Strain as a vector to express a fusion protein of <i>Y. pestis</i> F1 and LcrV antigens. We showed that homologous prime-boost vaccination with this vaccine provided potent protection in mice against lethal respiratory challenge with virulent <i>Y. pestis</i>. Here, we report on the immunogenicity and efficacy of rLVS Δ<i>capB</i>/Yp F1-V and additional LVS Δ<i>capB</i>-vectored vaccine candidates in mice. We demonstrate that three homologous prime-boost immunizations with an optimized dose of rLVS Δ<i>capB</i>/Yp F1-V provided complete protection against pneumonic plague in a stringent mouse model, outperforming other candidates and matching the survival efficacy of the toxic and unlicensed live attenuated <i>Y. pestis</i> EV76 strain vaccine; moreover, mice immunized with the rLVS Δ<i>capB</i>/Yp F1-V vaccine had minimal weight loss post-challenge that was significantly less than mice immunized with the EV76 vaccine. Protection induced by rLVS Δ<i>capB</i>/Yp F1-V correlates with F1 and LcrV-specific serum antibody levels. Our results highlight the potential of rLVS Δ<i>capB</i>/Yp F1-V to address the unmet need for a plague vaccine.
DOI: 10.6084/m9.figshare.29148999.v1
title: rLVS Δ<i>capB</i>/Yp F1-V single vector platform vaccine expressing <i>Yersinia pestis</i> F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli

description: <i>Yersinia pestis</i>, the causative agent of plague, is classified as a Tier I Select Agent of bioterrorism and is among a few pathogens of high concern as a potential cause of a future pandemic. Currently, there is no licensed vaccine against plague. Previously, we developed a live attenuated vaccine candidate, rLVS Δ<i>capB</i>/Yp F1-V, that utilizes a highly attenuated <i>capB</i> mutant of <i>Francisella tularensis</i> Live Vaccine Strain as a vector to express a fusion protein of <i>Y. pestis</i> F1 and LcrV antigens. We showed that homologous prime-boost vaccination with this vaccine provided potent protection in mice against lethal respiratory challenge with virulent <i>Y. pestis</i>. Here, we report on the immunogenicity and efficacy of rLVS Δ<i>capB</i>/Yp F1-V and additional LVS Δ<i>capB</i>-vectored vaccine candidates in mice. We demonstrate that three homologous prime-boost immunizations with an optimized dose of rLVS Δ<i>capB</i>/Yp F1-V provided complete protection against pneumonic plague in a stringent mouse model, outperforming other candidates and matching the survival efficacy of the toxic and unlicensed live attenuated <i>Y. pestis</i> EV76 strain vaccine; moreover, mice immunized with the rLVS Δ<i>capB</i>/Yp F1-V vaccine had minimal weight loss post-challenge that was significantly less than mice immunized with the EV76 vaccine. Protection induced by rLVS Δ<i>capB</i>/Yp F1-V correlates with F1 and LcrV-specific serum antibody levels. Our results highlight the potential of rLVS Δ<i>capB</i>/Yp F1-V to address the unmet need for a plague vaccine.
DOI: 10.6084/m9.figshare.29537929
title: Interventions targeting healthcare worker influenza vaccination: A systematic review

description: Healthcare workers (HCWs) have notably low influenza vaccination coverage rates (VCR) despite influenza being one of the world’s deadliest viruses. Interventions have attempted to tackle this issue, yet they have been unsuccessful in reaching desirable HCW VCR. In a systematic review, we aimed to understand and examine the specific behavior change methods of interventions that impact HCW VCR. Based on 86 studies, we identified 35 different behavior change methods. Although meta-analyses were not possible, the results suggest that interventions using rewards, nudging, or mass-media persuasion were most effective. Mandates, though one of the most effective methods, was not the most effective. Additionally, in the studies from 2016 onward there was a shift away from mandates and toward more autonomy-supportive methods. Ultimately, more research is needed to understand what methods are best for increasing HCW VCR globally. What is essential is the correct fit between identified psychosocial determinants and the method for change, considering the parameters of those methods in their application.
DOI: 10.6084/m9.figshare.29537929.v1
title: Interventions targeting healthcare worker influenza vaccination: A systematic review

description: Healthcare workers (HCWs) have notably low influenza vaccination coverage rates (VCR) despite influenza being one of the world’s deadliest viruses. Interventions have attempted to tackle this issue, yet they have been unsuccessful in reaching desirable HCW VCR. In a systematic review, we aimed to understand and examine the specific behavior change methods of interventions that impact HCW VCR. Based on 86 studies, we identified 35 different behavior change methods. Although meta-analyses were not possible, the results suggest that interventions using rewards, nudging, or mass-media persuasion were most effective. Mandates, though one of the most effective methods, was not the most effective. Additionally, in the studies from 2016 onward there was a shift away from mandates and toward more autonomy-supportive methods. Ultimately, more research is needed to understand what methods are best for increasing HCW VCR globally. What is essential is the correct fit between identified psychosocial determinants and the method for change, considering the parameters of those methods in their application.
DOI: 10.6084/m9.figshare.30136579
title: Managing allergy-related COVID-19 vaccine hesitancy: A multi-methods analysis of practitioner notes and referral outcomes

description: This study examines healthcare practitioners’ decision-making processes when managing vaccine-hesitant patients concerned about allergic reactions to COVID-19 vaccines. A multi-methods secondary data analysis was conducted combining quantitative referral trends and qualitative thematic analysis of health practitioner recorded notes. Anonymized data from 326 individuals referred to an interim COVID-19 vaccine allergy advice service based in Herefordshire and Worcestershire, UK, were analyzed. Quantitative data included referral patterns and vaccination outcomes, while qualitative data consisted of thematic analysis of free-text health practitioner notes documenting patient concerns and practitioner decision-making. Of the referred cases, 23.3% were advised to proceed with vaccination in primary care without precaution, 29% with additional precautions such as antihistamines and extended observation. Hospital-based vaccination was only recommended for 0.9%, typically for individuals with complex allergy histories. In 22.7%, cases were escalated to a multidisciplinary team that mainly advised vaccination in primary care with precautions or in hospital settings. Notably, no cases resulted in recommendations against vaccination. The qualitative analysis of health practitioner free text notes developed three themes: diverse presentation of allergies, complex allergy histories, and patient anxiety and lack of trust. Themes suggest healthcare practitioners face significant challenges in clinical decision-making with these patients and highlight the complexity of managing vaccine hesitancy. This study underscores the need for enhanced training and standardized documentation processes to support healthcare practitioners in managing allergy-related vaccine hesitancy. Public health messaging should proactively address misconceptions about vaccines as they relate to allergies, to build trust and reduce hesitancy.
DOI: 10.6084/m9.figshare.30136579.v1
title: Managing allergy-related COVID-19 vaccine hesitancy: A multi-methods analysis of practitioner notes and referral outcomes

description: This study examines healthcare practitioners’ decision-making processes when managing vaccine-hesitant patients concerned about allergic reactions to COVID-19 vaccines. A multi-methods secondary data analysis was conducted combining quantitative referral trends and qualitative thematic analysis of health practitioner recorded notes. Anonymized data from 326 individuals referred to an interim COVID-19 vaccine allergy advice service based in Herefordshire and Worcestershire, UK, were analyzed. Quantitative data included referral patterns and vaccination outcomes, while qualitative data consisted of thematic analysis of free-text health practitioner notes documenting patient concerns and practitioner decision-making. Of the referred cases, 23.3% were advised to proceed with vaccination in primary care without precaution, 29% with additional precautions such as antihistamines and extended observation. Hospital-based vaccination was only recommended for 0.9%, typically for individuals with complex allergy histories. In 22.7%, cases were escalated to a multidisciplinary team that mainly advised vaccination in primary care with precautions or in hospital settings. Notably, no cases resulted in recommendations against vaccination. The qualitative analysis of health practitioner free text notes developed three themes: diverse presentation of allergies, complex allergy histories, and patient anxiety and lack of trust. Themes suggest healthcare practitioners face significant challenges in clinical decision-making with these patients and highlight the complexity of managing vaccine hesitancy. This study underscores the need for enhanced training and standardized documentation processes to support healthcare practitioners in managing allergy-related vaccine hesitancy. Public health messaging should proactively address misconceptions about vaccines as they relate to allergies, to build trust and reduce hesitancy.
DOI: 10.6084/m9.figshare.29580356
title: Economic evaluations of vaccines against respiratory infections in adults in Southeast Asia: A systematic review

description: Respiratory infections significantly impact adult health in Southeast Asia, yet vaccine coverage remains low. This systematic review evaluated the economic evaluations of vaccines targeting respiratory infections in the region. A comprehensive search was conducted across several databases, including MEDLINE/PubMed, EMBASE, NHSEED, CINAHL, EconLit, Web of Science, Scopus, and Cochrane Library, up to April 24, 2024. Nineteen eligible studies were identified, focusing primarily on influenza (8 studies) and COVID-19 vaccines (7 studies), with fewer studies on pneumococcal (2 studies), varicella (1 study), and pertussis (1 study) vaccines. Overall, influenza, COVID-19 (boosters), and pneumococcal vaccines were found to be cost-effective or highly cost-effective compared to no-vaccine or no-booster scenarios. The only study on maternal pertussis vaccination found it not to be cost-effective. The most common parameters considered in sensitivity analyses were vaccine efficacy and discount rates. This review highlights the economic evaluations of influenza, COVID-19, and pneumococcal vaccines in Southeast Asia, providing essential evidence to guide vaccine policy. Future studies should address limitations in model selection, incorporate herd immunity, ensure the model validation (i.e. validity of cost and benefit measurements), and explore the cost-effectiveness of other vaccines across the region.
DOI: 10.6084/m9.figshare.29580356.v1
title: Economic evaluations of vaccines against respiratory infections in adults in Southeast Asia: A systematic review

description: Respiratory infections significantly impact adult health in Southeast Asia, yet vaccine coverage remains low. This systematic review evaluated the economic evaluations of vaccines targeting respiratory infections in the region. A comprehensive search was conducted across several databases, including MEDLINE/PubMed, EMBASE, NHSEED, CINAHL, EconLit, Web of Science, Scopus, and Cochrane Library, up to April 24, 2024. Nineteen eligible studies were identified, focusing primarily on influenza (8 studies) and COVID-19 vaccines (7 studies), with fewer studies on pneumococcal (2 studies), varicella (1 study), and pertussis (1 study) vaccines. Overall, influenza, COVID-19 (boosters), and pneumococcal vaccines were found to be cost-effective or highly cost-effective compared to no-vaccine or no-booster scenarios. The only study on maternal pertussis vaccination found it not to be cost-effective. The most common parameters considered in sensitivity analyses were vaccine efficacy and discount rates. This review highlights the economic evaluations of influenza, COVID-19, and pneumococcal vaccines in Southeast Asia, providing essential evidence to guide vaccine policy. Future studies should address limitations in model selection, incorporate herd immunity, ensure the model validation (i.e. validity of cost and benefit measurements), and explore the cost-effectiveness of other vaccines across the region.
DOI: 10.6084/m9.figshare.29408751
title: Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

description: The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD protection is recommended for all infants with nirsevimab given preferential recommendation over RSVpreF. We evaluated cost-effectiveness of various intervention strategies to prevent RSV in the Netherlands. We employed a cohort model to evaluate clinical and economic outcomes associated with RSV-LRTD during the first year of life among infants receiving RSVpreF with complementary nirsevimab and, alternatively, nirsevimab alone versus no intervention. Model inputs, based principally on Dutch data, include rates of disease, case-fatality, general mortality; disutility; and costs of interventions, medical care, treatment-related travel, and disease-associated work loss. Uptake of interventions assumed 70%; effectiveness was based on a published study using Phase III trial data. Analyses were conducted from the societal perspective using 2023 EUR; annual discount rates were 3% for costs and 1.5% for quality-adjusted life-years (QALYs). With no intervention, there were 10,482 RSV-LRTD cases with total associated costs of € 17.4M. Nirsevimab alone prevented 4,905 cases, yielding 100 QALYs; total costs increased by € 59.3M due to high intervention costs and cost-effectiveness was € 592,404/QALY (vs. no intervention). RSVpreF with complementary nirsevimab for infants prevented 4,723 cases, yielding 108 QALYs; total costs increased by € 35.5M and cost-effectiveness was € 329,187/QALY (vs. no intervention). Maternal RSVpreF with complementary nirsevimab was more cost-effective than nirsevimab alone.